Jiangxi Synergy Pharmaceutical Co Ltd - Asset Resilience Ratio
Jiangxi Synergy Pharmaceutical Co Ltd (300636) has an Asset Resilience Ratio of 4.68% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Jiangxi Synergy Pharmaceutical Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Jiangxi Synergy Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 300636 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Jiangxi Synergy Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Jiangxi Synergy Pharmaceutical Co Ltd (300636) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥155.13 Million | 4.68% |
| Total Liquid Assets | CN¥155.13 Million | 4.68% |
Asset Resilience Insights
- Limited Liquidity: Jiangxi Synergy Pharmaceutical Co Ltd maintains only 4.68% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jiangxi Synergy Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jiangxi Synergy Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Jiangxi Synergy Pharmaceutical Co Ltd (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Jiangxi Synergy Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.21% | CN¥40.08 Million ≈ $5.87 Million |
CN¥3.32 Billion ≈ $485.97 Million |
+0.60pp |
| 2024-12-31 | 0.60% | CN¥20.05 Million ≈ $2.93 Million |
CN¥3.32 Billion ≈ $485.75 Million |
-- |
About Jiangxi Synergy Pharmaceutical Co Ltd
Jiangxi Synergy Pharmaceutical Co., Ltd. engages in research and development, production, and sales of chemical raw materials and pharmaceutical intermediates in China and internationally. The company offers nervous system drugs, digestive system medications, antipyretic analgesics and non-steroidal anti-inflammatory analgesics, antihypertensive drugs, anticoagulants, hypoglycemic drugs, antidepr… Read more